Recommendation of mavacamten posology by model-based analyses in adults with obstructive hypertrophic cardiomyopathy.
Ontology highlight
ABSTRACT: Mavacamten is the first cardiac myosin inhibitor approved by the US Food and Drug Administration for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). The phase III EXPLORER-HCM (NCT03470545) study used a dose-titration scheme based on mavacamten exposure and echocardiographic assessment of Valsalva left ventricular outflow tract gradient (VLVOTg) and left ventricular ejection fraction (LVEF). Using population pharmacokinetic/exposure-response modeling and simulations of virtual patients, this in silico study evaluated alternative dose-titration regimens for mavacamten, including regimens that were guided by echocardiographic measures only. Mavacamten exposure-response models for VLVOTg (efficacy) and LVEF (safety) were developed using patient data fro
SUBMITTER: Merali S
PROVIDER: S-EPMC11533099 | biostudies-literature | 2024 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA